Recent studies have centered on the convergence of glucagon-like peptide-1|GIP|glucagon receptor stimulant therapies and dopaminergic signaling. While GIP stimulators are commonly employed for managing type 2 diabetes mellitus, their potential impacts on reward circuits, specifically influenced by dopaminergic systems, are receiving considerable… Read More